Adenocarcinoma of Esophagogastric Junction Clinical Trial
Official title:
Efficacy and Safety of PD-1 Combined With Long-term Concurrent Neoadjuvant Chemoradiotherapy and Chemotherapy in the Treatment of Resectable Locally Advanced Esophagogastric Junction Adenocarcinomaļ¼ A Phase II Study
The purpose of this study was to evaluate the effect and safety of concurrent PD-1 antibody-based long-term radiotherapy followed by 2 cycles SOX with PD-1 in patients with locally advanced adenocarcinoma of esophagogastric junction.
The incidence of adenocarcinoma of the esophagogastric junction (AEG) is increasing in Asian countries and Western Contries. Surgical resection is the most important treatment for AEG. However, the recurrence rate is high when surgery is performed alone. The results of CLASSIC, MAGIC, FLOT4, JCOG0501, PRODIGY, RESOLVE, CROSS trial showed that perioperative chemotherapy and pre- or postoperative chemoradiotherapy significantly increase the overall survival rate and disease free survival rate compared to surgery alone. Radiotherapy and immunotherapy can increase sensitivity to each other, and several clinical studies have also showed that PD-1 antibody may significantly prolongs the life.Thus the investigators plan to conduct this clinical trial to evaluate the effect and safety of concurrent PD-1 antibody-based long-term radiotherapy followed by 2 cycles SOX with PD-1 in patients with locally advanced adenocarcinoma of esophagogastric junction. Subjects will receive long-term radiotherapy (5w) concurrent with PD-1 antibody for 2 cycles, then receive two cycles of SOX regimen combined PD-1 after a week's rest. Surgery will be performed 2 weeks after the last cycle of neoadjuvant treatment. Adjuvant treatment will be started 3 to 8 weeks after surgery, and SOX regimen will be given for 4 cycles. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05829213 -
A Modified Esophagogastric Reconstruction Method After Laparoscopic Proximal Gastrectomy
|
N/A | |
| Recruiting |
NCT05729646 -
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT04891900 -
TQB2450 (PD-L1 Inhibitor) Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
|
N/A | |
| Active, not recruiting |
NCT01095120 -
Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05970627 -
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
| Recruiting |
NCT03734913 -
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06300879 -
A Prospective Study on Esophagogastrostomy by an Innovative Surgical Technique
|
N/A | |
| Recruiting |
NCT05715931 -
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT06222944 -
Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA
|
Phase 2 | |
| Active, not recruiting |
NCT03302403 -
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
|
N/A | |
| Recruiting |
NCT05872685 -
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
|
Phase 2 | |
| Recruiting |
NCT04910789 -
Transhiatal/Transabdominal Approach Compare With Thoracoabdominal Approach for Siewert II Adenocarcinoma of Esophagogastric Junction
|
N/A | |
| Recruiting |
NCT04813523 -
Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma
|
Phase 2 |